CY1112958T1 - Ιατρικες συνθεσεις που περιλαμβανουν τακρινη ή ντονεπεζιλη για βελτιωση εγκεφαλικης λειτουργιας - Google Patents

Ιατρικες συνθεσεις που περιλαμβανουν τακρινη ή ντονεπεζιλη για βελτιωση εγκεφαλικης λειτουργιας

Info

Publication number
CY1112958T1
CY1112958T1 CY20121100432T CY121100432T CY1112958T1 CY 1112958 T1 CY1112958 T1 CY 1112958T1 CY 20121100432 T CY20121100432 T CY 20121100432T CY 121100432 T CY121100432 T CY 121100432T CY 1112958 T1 CY1112958 T1 CY 1112958T1
Authority
CY
Cyprus
Prior art keywords
donapezil
cerebral
ingredient
integer
optionally substituted
Prior art date
Application number
CY20121100432T
Other languages
English (en)
Inventor
Yasushi Nakada
Masaya Nakagawa
Satoshi Ono
Original Assignee
Toyama Chemical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co., Ltd. filed Critical Toyama Chemical Co., Ltd.
Publication of CY1112958T1 publication Critical patent/CY1112958T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)

Abstract

Παράγωγο αλκύλ αιθέρα που αντιπροσωπεύεται από τον τύπο:
CY20121100432T 2002-06-14 2012-05-08 Ιατρικες συνθεσεις που περιλαμβανουν τακρινη ή ντονεπεζιλη για βελτιωση εγκεφαλικης λειτουργιας CY1112958T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002173483 2002-06-14
EP03760132A EP1514542B1 (en) 2002-06-14 2003-04-03 Medicinal composition comprising Tacrine or Donepezil for improving brain function.

Publications (1)

Publication Number Publication Date
CY1112958T1 true CY1112958T1 (el) 2016-04-13

Family

ID=29727916

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20121100432T CY1112958T1 (el) 2002-06-14 2012-05-08 Ιατρικες συνθεσεις που περιλαμβανουν τακρινη ή ντονεπεζιλη για βελτιωση εγκεφαλικης λειτουργιας
CY181100871T CY1120591T1 (el) 2002-06-14 2018-08-21 Ιατρικη συνθεση για βελτιωση λειτουργιας εγκεφαλου

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY181100871T CY1120591T1 (el) 2002-06-14 2018-08-21 Ιατρικη συνθεση για βελτιωση λειτουργιας εγκεφαλου

Country Status (23)

Country Link
US (3) US7342043B2 (el)
EP (2) EP2389937B1 (el)
JP (1) JP4675103B2 (el)
KR (1) KR100935615B1 (el)
CN (1) CN100375619C (el)
AT (1) ATE546140T1 (el)
AU (1) AU2003236364C1 (el)
BR (1) BRPI0311780B8 (el)
CA (1) CA2488120C (el)
CY (2) CY1112958T1 (el)
DK (2) DK2389937T3 (el)
ES (2) ES2379948T3 (el)
HU (1) HUE041842T2 (el)
IL (1) IL165589A (el)
MX (1) MXPA04012534A (el)
NO (1) NO333504B1 (el)
NZ (1) NZ537090A (el)
PL (1) PL217394B1 (el)
PT (2) PT2389937T (el)
SI (2) SI2389937T1 (el)
TR (1) TR201816386T4 (el)
WO (1) WO2003105830A1 (el)
ZA (1) ZA200409901B (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL215264B1 (pl) * 2001-10-19 2013-11-29 Toyama Chemical Co Ltd Pochodne eteru alkilowego lub ich sole, sposób ich wytwarzania oraz kompozycja farmaceutyczna
SI2389937T1 (sl) 2002-06-14 2018-10-30 Toyama Chemical Co., Ltd, Farmacevtska sestava za izboljšanje možganske funkcije
KR101096528B1 (ko) * 2003-04-17 2011-12-20 토야마 케미칼 컴퍼니 리미티드 알킬에테르 유도체 또는 그 염을 함유하는 망막신경질환의예방·치료제
US7435837B2 (en) 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
EP2258359A3 (en) * 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US8119625B2 (en) * 2006-04-26 2012-02-21 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
WO2007125913A1 (ja) * 2006-04-26 2007-11-08 Toyama Chemical Co., Ltd. アルキルエーテル誘導体またはその塩を含有する神経細胞新生誘導剤および精神障害治療剤
JP5255441B2 (ja) * 2006-08-04 2013-08-07 富山化学工業株式会社 アルキルエーテル誘導体またはその塩を含有するプロテインキナーゼｃ活性促進剤
US20090221554A1 (en) * 2008-02-28 2009-09-03 Zenyaku Kogyo Kabushiki Kaisha Method of treating cognitive impairment
PT2287160E (pt) * 2008-05-28 2014-06-24 Toyama Chemical Co Ltd Derivado de óxido de benzotiofeno e os seus sais
EP2885267B1 (en) 2012-07-12 2018-09-05 Concert Pharmaceuticals, Inc. Deuterated idebenone
SG10201907035TA (en) * 2014-01-31 2019-09-27 Fujifilm Toyama Chemical Co Ltd Post nerve injury rehabilitation effect-enhancing agent comprising alkyl ether derivative or salt thereof
EP3636262A4 (en) 2017-06-02 2020-06-10 FUJIFILM Toyama Chemical Co., Ltd. AGENT FOR PREVENTING OR TREATING ALZHEIMER-LIKE DEMENTIA
BR112019024851A2 (pt) 2017-06-02 2020-06-09 Fujifilm Toyama Chemical Co Ltd agente para evitar ou tratar atrofia cerebral
IL270910B2 (en) 2017-06-02 2024-03-01 Fujifilm Toyama Chemical Co Ltd 1-(3-(2-(1-benzothiophene-5-yl)ethoxy)propyl)aztidine-3-ol or a salt thereof for use in suppressing cerebral atrophy
RU2019138538A (ru) 2017-06-02 2021-07-09 ФУДЖИФИЛМ Тояма Кемикал Ко., Лтд. СРЕДСТВО ДЛЯ УМЕНЬШЕНИЯ КОЛИЧЕСТВА АМИЛОИДНОГО β-БЕЛКА
KR20220101001A (ko) 2017-06-02 2022-07-18 후지필름 도야마 케미컬 가부시키가이샤 타우병증 예방 또는 치료제
SG11202000193UA (en) * 2017-07-08 2020-02-27 Massachusetts Gen Hospital Screening platform to identify therapeutic drugs or agents for treatment of alzheimer's disease
EP3705121B1 (en) 2017-10-30 2023-08-30 FUJIFILM Toyama Chemical Co., Ltd. Emopamil binding protein binding agent and use thereof
CN110464834B (zh) * 2019-09-04 2022-12-02 北京豪思生物科技股份有限公司 铜蓝蛋白联合多奈哌齐的应用
KR20220040291A (ko) 2020-09-23 2022-03-30 씨엔지바이오 주식회사 4-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물
KR20220040294A (ko) 2020-09-23 2022-03-30 씨엔지바이오 주식회사 6-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74497A (en) 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
US5177082A (en) 1985-11-05 1993-01-05 Yu Chao Mei Huperzines and analogs
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JPH0210827A (ja) 1988-06-29 1990-01-16 Matsushita Electron Corp 半導体装置の製造方法
NZ232493A (en) * 1989-02-14 1992-06-25 Toyama Chemical Co Ltd Aryl- or heterocyclyl-substituted 1,2-ethanediol derivatives and pharmaceutical compositions
US5280032A (en) 1989-02-14 1994-01-18 Toyama Chemical Co., Ltd. 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same
JP2887492B2 (ja) 1990-02-05 1999-04-26 富山化学工業株式会社 １，２―エタンジオール誘導体およびその塩
JP2913196B2 (ja) 1989-04-26 1999-06-28 富山化学工業株式会社 １，２−エタンジオール誘導体またはその塩
US4914102A (en) * 1989-09-28 1990-04-03 Hoechst Roussel Pharmaceuticals, Inc. N-aminocarbamates related to physostigmine, pharmacentical compositions and use
JP3044055B2 (ja) * 1990-08-09 2000-05-22 富山化学工業株式会社 １，２―エタンジオール誘導体およびその塩
JPH0676401B2 (ja) 1990-10-19 1994-09-28 エスエス製薬株式会社 キノリン誘導体及びこれを含有する医薬
TW197435B (el) 1990-11-22 1993-01-01 Takeda Pharm Industry Co Ltd
DE4111861A1 (de) 1991-04-11 1992-10-15 Schwabe Willmar Gmbh & Co Benzopyranone, verfahren zu ihrer herstellung und verwendung
JP2925363B2 (ja) 1991-07-09 1999-07-28 キヤノン株式会社 画像処理方法及び装置
DE4136288A1 (de) 1991-11-04 1993-05-06 Troponwerke Gmbh & Co Kg, 5000 Koeln, De Kombination von calciumantagonisten mit cholinesterase-inhibitoren
JP3232830B2 (ja) 1993-11-30 2001-11-26 三菱電機株式会社 フレキシブルディスク装置のキャリッジ機構
PL187004B1 (pl) 1994-10-25 2004-04-30 Toyama Chemical Co Ltd Nowe pochodne 1,2-etanodiolu oraz kompozycje farmaceutyczne je zawierające
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
WO1997030703A1 (fr) * 1996-02-20 1997-08-28 Toyama Chemical Co., Ltd. Agent ameliorant les fonctions cerebrales contenant des derives de 1,2-ethanediol ou des sels de celui-ci
NZ333513A (en) 1996-07-10 2000-04-28 Schering Corp 1,4-di-substituted piperidines and medicaments useful as muscarinic antagonists
PL331536A1 (en) * 1996-08-15 1999-07-19 Schering Corp Muscarinic antagonists with an etheric bond
JPH10259126A (ja) 1997-01-17 1998-09-29 Takeda Chem Ind Ltd アルツハイマー病治療・予防剤
US20030092737A1 (en) 1997-11-14 2003-05-15 Pierre Maffrand Jean Combination of active ingredients for the treatment of senile dementia of the Alzheimer type
CO4980891A1 (es) 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
AU1506499A (en) 1997-12-12 1999-07-05 Toyama Chemical Co. Ltd. Alkyl ether derivatives or salts thereof and calcium antagonists containing the same
KR100641352B1 (ko) * 1999-06-11 2006-11-02 토야마 케미칼 컴퍼니 리미티드 Ｎ-알콕시알킬-ｎ,ｎ-디알킬아민 유도체 또는 그 염, 및이를 함유하는 신경퇴행성질환 치료제
PL215264B1 (pl) 2001-10-19 2013-11-29 Toyama Chemical Co Ltd Pochodne eteru alkilowego lub ich sole, sposób ich wytwarzania oraz kompozycja farmaceutyczna
SI2389937T1 (sl) 2002-06-14 2018-10-30 Toyama Chemical Co., Ltd, Farmacevtska sestava za izboljšanje možganske funkcije
KR101096528B1 (ko) 2003-04-17 2011-12-20 토야마 케미칼 컴퍼니 리미티드 알킬에테르 유도체 또는 그 염을 함유하는 망막신경질환의예방·치료제
WO2007125913A1 (ja) 2006-04-26 2007-11-08 Toyama Chemical Co., Ltd. アルキルエーテル誘導体またはその塩を含有する神経細胞新生誘導剤および精神障害治療剤
US8119625B2 (en) 2006-04-26 2012-02-21 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof

Also Published As

Publication number Publication date
WO2003105830A1 (ja) 2003-12-24
IL165589A (en) 2012-04-30
JP4675103B2 (ja) 2011-04-20
SI1514542T1 (sl) 2012-06-29
AU2003236364A1 (en) 2003-12-31
BR0311780A (pt) 2005-03-15
PL217394B1 (pl) 2014-07-31
NO333504B1 (no) 2013-06-24
AU2003236364B2 (en) 2008-08-21
CA2488120C (en) 2012-04-17
US20080103126A1 (en) 2008-05-01
EP1514542B1 (en) 2012-02-22
CY1120591T1 (el) 2019-12-11
BRPI0311780B1 (pt) 2017-09-26
EP1514542A4 (en) 2009-06-03
ZA200409901B (en) 2006-07-26
DK2389937T3 (en) 2018-11-12
TR201816386T4 (tr) 2018-11-21
HUE041842T2 (hu) 2019-05-28
KR100935615B1 (ko) 2010-01-07
SI2389937T1 (sl) 2018-10-30
PT1514542E (pt) 2012-03-27
CN100375619C (zh) 2008-03-19
JPWO2003105830A1 (ja) 2005-10-13
MXPA04012534A (es) 2005-04-19
CN1662232A (zh) 2005-08-31
AU2003236364C1 (en) 2009-12-24
BRPI0311780B8 (pt) 2021-05-25
CA2488120A1 (en) 2003-12-24
NO20045158L (no) 2005-03-10
USRE42327E1 (en) 2011-05-03
ATE546140T1 (de) 2012-03-15
EP2389937A1 (en) 2011-11-30
PL372934A1 (en) 2005-08-08
US7342043B2 (en) 2008-03-11
US7834053B2 (en) 2010-11-16
NZ537090A (en) 2006-02-24
ES2685923T3 (es) 2018-10-15
ES2379948T3 (es) 2012-05-07
US20050250843A1 (en) 2005-11-10
IL165589A0 (en) 2006-01-15
KR20050010877A (ko) 2005-01-28
DK1514542T3 (da) 2012-04-10
EP2389937B1 (en) 2018-08-15
PT2389937T (pt) 2018-10-26
EP1514542A1 (en) 2005-03-16

Similar Documents

Publication Publication Date Title
CY1120591T1 (el) Ιατρικη συνθεση για βελτιωση λειτουργιας εγκεφαλου
PT1259489E (pt) Compostos azapoliciclicos condensados con arilo.
PA8627201A1 (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
TR199900255T2 (xx) Muskarinik antagonistleri
ATE440834T1 (de) Substituierte arylaminderivate und verwendungsverfahren
CA2501799A1 (en) Pyrazole compounds for treatment of neurodegenerative disorders
SG161217A1 (en) New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents
CA2534532A1 (en) Compounds for the treatment of neurodegenerative disorders
MXPA05012196A (es) Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos.
MY140835A (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
TW200602297A (en) Sulfonamide compounds for the treatment of neurodegenerative disorders
ATE402150T1 (de) Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen
WO2005097114A3 (en) Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders
NO20081845L (no) Imidazolforbindelser for behandling av neurologiske lidelser
DE60231054D1 (de) Piperidinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzung zur behandlung von alzheimer-krankheit, die diese derivate enthält
DE69315363D1 (de) Amphotere tricyclische Verbindungen als antihistaminische und antiallergische Mittel
WO2005095361A8 (en) Isoxazole- and isothiazole-amine compounds for the treatment of neurodegenerative disorders
NO891071L (no) Fremgangsmaate for fremstilling av 4,5,6,7-tetrahydro-isotiazolo(4,5-c)-pyridinderivater og isomere.
DE602005012826D1 (de) Neue mao-b-hemmer
Toth et al. 1-Oxa-3, 8-diazaspiro [4.5] decan-2-one derivatives with a potent inhibitory effect on neural Ca-uptake and protecting action against TET-induced brain edema and memory and learning deficits
UY26785A1 (es) Derivados bicíclicos sustituidos para el tratamiento del crecimiento celular anormal